AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord

AstraZeneca's Ultomiris Showed Zero Relapses In Patients With Chronic Disorder Of Brain, Spinal Cord
  • AstraZeneca Plc AZN posted detailed results from the Phase 3 CHAMPION-NMOSD trial of Ultomiris (ravulizumab) For neuromyelitis optica spectrum disorder (NMOSD).
  • NMOSD is an autoimmune disease that affects the central nervous system (CNS), including the spine and optic nerves.
  • The data showed that Ultomiris significantly reduced relapse risk in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) NMOSD, compared to the external placebo arm from the pivotal Soliris PREVENT clinical trial. 
  • Data showed zero adjudicated relapses were observed among Ultomiris patients with a median treatment duration of 73 weeks (relapse risk reduction: 98.6%). Additionally, 100% of patients receiving Ultomiris remained relapse-free at 48 weeks, compared to 63% of patients in the external placebo arm.
  • The CHAMPION-NMOSD trial also met key secondary efficacy endpoints, including adjudicated on-trial annualized relapse rate and clinically important change from baseline in the ability to walk.
  • Price Action: AZN shares are down 0.20% at $57.85 on the last check Thursday.

Posted In: BriefsBiotechLarge CapNewsHealth CareGeneral